Analyst Reco. AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Market Closed - Nasdaq Other stock markets 21:30:00 03/05/2024 BST			5-day change	1st Jan Change
4.03 ^USD	+4.68%		+7.18%	-29.42%

05-01	AbCellera Biologics Inc., Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies	CI
03-11	AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $9	02-22	MT
Stifel Lowers Price Target on AbCellera Biologics to $17 From $21, Maintains Buy Rating	02-21	MT
KeyBanc Initiates AbCellera Biologics at Overweight With $6 Price Target, Cites 'Robust' Platform, 'Attractive' Valuation	12-05	MT
Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target	13/10/23	MT
Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating	31/08/23	MT
Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating	04/08/23	MT
Berenberg Bank Adjusts AbCellera Biologics Price Target to $34 From $38, Maintains Buy Rating	04/08/23	MT
Credit Suisse Lowers AbCellera Biologics' Price Target to $28 From $34, Keeps Outperform Rating	05/05/23	MT
Cowen Starts AbCellera Biologics at Outperform	28/02/23	MT
BMO Capital Cuts Price Target on AbCellera Biologics to $32 From $40, Maintains Outperform Rating	22/02/23	MT
Berenberg Bank Adjusts AbCellera Biologics' Price Target to $38 From $43, Maintains Buy Rating	22/02/23	MT
Prospect of Further Federal Reserve Interest Rate Increases Pressuring Exchange-Traded Funds, Equity Futures	24/01/23	MT
Fed Rate Outlook, China Optimism Lift Exchange-Traded Funds, Equity Futures Pre-Bell	20/01/23	MT
SVB Securities Adjusts Price Target on AbCellera Biologics to $18 From $20, Maintains Outperform Rating	06/01/23	MT
Goldman Sachs Initiates AbCellera Biologics at Buy With $30 Price Target	15/12/22	MT
Truist Securities Starts AbCellera Biologics at Buy With $29 Price Target	16/11/22	MT
SVB Securities Raises Price Target on AbCellera Biologics to $20 From $13, Maintains Outperform Rating	09/11/22	MT
Piper Sandler Trims Price Target on AbCellera Biologics to $21 From $22, Maintains Overweight Rating	01/11/22	MT
Credit Suisse Lowers AbCellera Biologics' PT to $34 from $40, Updates Model with Q2 Actuals, Adjusts Near-Term Program Projections; Keeps Outperform Rating	10/08/22	MT
Piper Sandler Adjusts Price Target on AbCellera Biologics to $22 From $21, Reiterates Overweight Rating	26/07/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Analyst Reco.

Filters